Evidence map›Paper›PMID 39448200›Full record

Trial reportJournal for immunotherapy of cancer2024

Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

Nicolas Zhou, Cheuk H Leung, William N William, Annikka Weissferdt, Apar Pataer, Myrna C B Godoy, Brett W Carter, Frank V Fossella, Anne S Tsao, George R Blumenschein and 27 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03158129 (Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03158129 phase2completednot on this map

Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2017 to 2024Enrolled101ConditionsStage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7ArmsCarboplatin, Cisplatin, Docetaxel, Ipilimumab, Nivolumab
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Perioperative Therapy in Oncogene-Driven Non-Small Cell Lung Cancer: Current Strategies and Unanswered Questions.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2025
    Review
  4. The role of immunotherapy in resectable non-small-cell lung cancer.Therapeutic advances in medical oncology · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Nicolas ZhouDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-8340-9113
Cheuk H LeungDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
William N WilliamDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA TCascone@MDAnderson.org william.william@medicos.oncoclinicas.com.
Annikka WeissferdtDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Apar PataerDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Myrna C B GodoyDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Brett W CarterDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Frank V FossellaDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anne S TsaoDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
George R BlumenscheinDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xiuning LeDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jianjun ZhangDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-7872-3477
Ferdinandos SkoulidisDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jonathan M KurieDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mehmet AltanDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-9229-156X
Charles LuDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bonnie S GlissonDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lauren A ByersDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yasir Y ElaminDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Reza J MehranDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David C RiceDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Garrett L WalshDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wayne L HofstetterDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jack A RothDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hai T TranDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jia WuDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Luisa M Solis SotoDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Humam KadaraDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Stephen G SwisherDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ara A VaporciyanDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Don L GibbonsDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Heather Y LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-5469-9214
John V HeymachDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marcelo V NegraoDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-8938-6699
Boris SepesiSarah Cannon Cancer Institute, Swedish Medical Center, Englewood, Colorado, USA.
Tina CasconeDepartment of Thoracic and Head and Neck Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA TCascone@MDAnderson.org william.william@medicos.oncoclinicas.com.ORCID http://orcid.org/0000-0003-3008-5407

Funding

Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung CancerR01CA262425 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CASCONE, TINA, WU, JIA · 2021 to 2025
$3.2M
Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma developmentU01CA264583 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Humam Kadara, Linghua Wang · 2022 to 2026
$2.1M
NCI NIH HHS R01 CA262425NCI NIH HHS U01 CA264583
6 · The paper itself

Abstract

backgroundNeoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the efficacy of neoadjuvant ICIs remains unclear. We report the influence of AGAs on treatment failure (TF) in patients with resectable NSCLC treated with neoadjuvant ICIs.

methodsTumor molecular profiles were obtained from patients with stage I-IIIA resectable NSCLC (American Joint Committee on Cancer seventh edition) treated with either neoadjuvant nivolumab (N, n=23) or nivolumab+ipilimumab (NI, n=21) followed by surgery in a previously reported phase-2 randomized study (NCT03158129). TF was defined as any progression of primary lung cancer after neoadjuvant ICI therapy in patients without surgery, radiographic and/or biopsy-proven primary lung cancer recurrence after surgery, or death from possibly treatment-related complications or from primary lung cancer since randomization. Tumors with AGAs (n=12) were compared with tumors without AGAs and non-profiled squamous cell carcinomas (non-AGAs+NP SCC, n=20).

resultsWith a median follow-up of 60.2 months, the overall TF rate was 34.1% (15/44). Tumor molecular profiling was retrospectively obtained in 47.7% (21/44) of patients and select AGAs were identified in 12 patients: 5 epidermal growth factor receptor

conclusionsPatients with NSCLC harboring select AGAs, including

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoadjuvant TherapyAgedFemaleGenomicsHumansImmune Checkpoint InhibitorsImmunotherapyMaleMiddle AgedImmune Checkpoint InhibitorsImmunotherapyIpilimumabLung CancerNivolumabRecurrence

Identifiers

PMID39448200
PMCPMC11499765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.